Navigation Links
At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed)

tual results may vary once the final and quality-controlled verification of data and analyses has been completed, the expense and uncertainty of obtaining regulatory approval, including from the FDA, and the possibility of having to conduct additional clinical trials. Further, even if regulatory approval is obtained, therapeutic products are generally subject to: stringent on-going governmental regulation, challenges in gaining market acceptance, and competition. Neurochem does not undertake any obligation to publicly update its forward-looking statements, whether as a result of new information, future events, or otherwise. Please see the Annual Information Form for further risk factors that might affect the Company and its business.

    For further information, please contact:


    Lise Hebert, PhD                          Tel: (450) 680-4572

    Vice President, Corporate Communications  

lhebert@neurochem.com

CONTACT: Lise Hebert, PhD, Vice President, Corporate Communications, (450)680-4572, lhebert@neurochem.com

Ticker Symbol: (:NRM.),(:NRMX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
6. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
7. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
8. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
9. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
10. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
11. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
Post Your Comments:
(Date:10/17/2014)... 2014 The following is being released ... The Green Park Collaborative (GPC) will bring ... payers, medical device and pharmaceutical companies, as well ... 12, 2015 at its first ever workshop on ... treatments.  Participants will discuss study designs to evaluate ...
(Date:10/17/2014)...  UBM Medica US announces that Endocrinology Network ... clinicians who treat patients with type 2 diabetes ... of insulin .  Nearly all patients ... – daily injections of one or more insulin ... function of pancreatic beta cells. Insulin is a very ...
(Date:10/17/2014)... -- Ameritox SM , the nation,s leader in medication monitoring ... , M.D., as Chief Medical Officer. In this role, ... for healthcare providers, patients and managed care plans.   ... variety of healthcare companies that have provided him with ... health sides of Ameritox,s business. He most recently served ...
Breaking Medicine Technology:Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3Ameritox Appoints New Chief Medical Officer 2
... Visica 2(TM) Treatment System Selected as Exclusive Cryoablation ... ... The American College of,Surgeons Oncology Group (ACOSOG) which just ... Phase II Trial Exploring,the Success of Cryoablation Therapy in the ...
... results to be presented at 2008 ICAAC/IDSA ... Sequella, Inc., a,clinical-stage biopharmaceutical company focused ... epidemic potential, announces the,successful demonstration of synergistic ... resulting from in vitro combination,studies of Sequella ...
Cached Medicine Technology:NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation 2NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation 3Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207 2
(Date:10/20/2014)... 2014 Unveiled at the Sept. 18 board ... conservatively estimates member hospital ROI on membership dues at 12.5. ... Center provides $12.50 in value to member hospitals. The calculation ... Member Dues)/Member Dues. , “This is the first time ... we think the methodology is really sound,” said Bill ...
(Date:10/20/2014)... 2014 Punzoné , the first line ... has a lot to celebrate this month. October marks Italian ... achievements and contributions of Americans of Italian heritage and Italians ... today it shares its favorite Italian cocktails and encourages everyone ... - even if it is only in a glass. ...
(Date:10/20/2014)... USA (PRWEB) October 20, 2014 Do ... track interventions? Here comes a wonderful app Metassessor for ... app development company helped its client “Intervention Development ... efficiently. The app is designed for iOS 4.3 or ... touch. This app is optimized for iPhone 5. It ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 The ... iPage ( http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the ... excellent platforms for those who want to buy ... same time. , The IT manager of Top10BestSEOHosting.com ... the most recommended suppliers for everyone. A lot ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 Dr. Babatunde ... Fund, welcomes news of a ceasefire agreement that is ... than 200 girls who were kidnapped from the north-eastern ... languished in captivity long enough, and it is high ... communities," stated Dr. Osotimehin. , "We owe it to ...
Breaking Medicine News(10 mins):Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2
...
...
...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 35G x 5/8in (.50 x 16mm)...
Medicine Products: